[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100505260":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":40,"centralContacts":51,"locations":61,"responsibleParty":113,"collaborators":116,"id":130,"slug":131,"hasResults":132,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":132,"sex":138,"minAge":139,"maxAge":21,"enrollmentInfo":140,"targetDuration":21,"studyType":143,"phases":144,"briefSummary":146,"conditions":147,"keywords":149,"overallStatus":64,"whyStopped":21,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":162},{"fullName":5,"class":6},"Cardiology Research UBC","OTHER",[8,17],{"label":9,"type":10,"description":11,"interventionNames":12},"Investigational arm guided by NT-proBNP result","ACTIVE_COMPARATOR","NT-proBNP drawn and if level elevated (\\>125 pg\u002Fml) a study visit with artificial intelligence (AI) echocardiogram, electrocardiogram (ECG), and heart failure (HF) focused examination conducted",[13,14,15,16],"Diagnostic Test: NT-proBNP","Diagnostic Test: AI echocardiogram","Diagnostic Test: electrocardiogram","Other: Cardiovascular physical examination",{"label":18,"type":19,"description":20,"interventionNames":21},"Routine care arm","NO_INTERVENTION","Participants will be remotely monitored for number of heart failure events",null,[23,28,32,36],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":21},"DIAGNOSTIC_TEST","NT-proBNP","blood sample to measure N-terminal prohormone of B-type natriuretic peptide at local laboratory",[9],{"type":24,"name":29,"description":30,"armGroupLabels":31,"otherNames":21},"AI echocardiogram","Artificial intelligence driven transthoracic echocardiogram",[9],{"type":24,"name":33,"description":34,"armGroupLabels":35,"otherNames":21},"electrocardiogram","tracing of electrical cardiac activity of the heart",[9],{"type":6,"name":37,"description":38,"armGroupLabels":39,"otherNames":21},"Cardiovascular physical examination","basic physiological measurements to include height (cm), weight (kg) and hip circumference (cm) and blood pressure (mmHg)",[9],[41,45,48],{"name":42,"affiliation":43,"role":44},"Nathaniel M Hawkins, MD","Associate Professor of Medicine, UBC Division of Cardiology","PRINCIPAL_INVESTIGATOR",{"name":46,"affiliation":47,"role":44},"Anique Ducharme, MD","Professor of Medicine, Univeriste de Montreal, Montreal Heart Institute",{"name":49,"affiliation":50,"role":44},"Serge LePage, MD","Centre Hospitalier Universite de Sherbrooke-Hopital Fleurimont",[52,57],{"name":53,"role":54,"phone":55,"phoneExt":21,"email":56},"Naomi Uchida, BSN","CONTACT","16048754521","naomi.uchida@ubc.ca",{"name":58,"role":54,"phone":59,"phoneExt":21,"email":60},"Jennifer Petterson","604-875-5104","jenny.petterson@vch.ca",[62,84,100],{"facility":63,"status":64,"city":65,"state":66,"zip":67,"country":68,"countryCode":69,"cosmosGeoPoint":70,"geoPoint":75,"contacts":76},"Vancouver General Hospital","RECRUITING","Vancouver","British Columbia","V5Z 1M9","Canada","CA",{"type":71,"coordinates":72},"Point",[73,74],-123.11934,49.24966,{"lat":74,"lon":73},[77,81],{"name":78,"role":54,"phone":79,"phoneExt":21,"email":80},"Nathaniel Hawkins, MD","604-875-5264","nat.hawkins@ubc.ca",{"name":82,"role":83,"phone":21,"phoneExt":21,"email":21},"Sean Virani, MD","SUB_INVESTIGATOR",{"facility":85,"status":86,"city":87,"state":88,"zip":89,"country":68,"countryCode":69,"cosmosGeoPoint":90,"geoPoint":94,"contacts":95},"Montreal Heart Institute","NOT_YET_RECRUITING","Montreal","Quebec","H1T 1C8",{"type":71,"coordinates":91},[92,93],-73.58781,45.50884,{"lat":93,"lon":92},[96],{"name":46,"role":54,"phone":97,"phoneExt":98,"email":99},"514-376-3330","3927","anique.ducharme@umontreal.ca",{"facility":101,"status":86,"city":102,"state":88,"zip":103,"country":68,"countryCode":69,"cosmosGeoPoint":104,"geoPoint":108,"contacts":109},"University of Sherbrooke","Sherbrooke","J1H 5N4",{"type":71,"coordinates":105},[106,107],-71.89908,45.40008,{"lat":107,"lon":106},[110],{"name":49,"role":54,"phone":111,"phoneExt":21,"email":112},"819-349-1788","serge.lepage@usherbrooke.ca",{"type":44,"investigatorFullName":114,"investigatorTitle":115,"investigatorAffiliation":5,"oldNameTitle":21,"oldOrganization":21},"Nathaniel Hawkins","Principal Investigator",[117,120,123,125,127,129],{"name":118,"class":119},"AstraZeneca","INDUSTRY",{"name":121,"class":122},"Centre for Cardiovascular Innovation","UNKNOWN",{"name":124,"class":122},"NHS Greater Glasgow & Clyde",{"name":126,"class":122},"HeartLife Foundation",{"name":128,"class":122},"Canadian Heart Function Alliance",{"name":85,"class":6},"100505260","multidisciplinary-approach-for-high-risk-patients-leading-to-early-diagnosis-of-canadians-in-heart-failure-100505260",false,"NCT05859048","Multidisciplinary Approach for High Risk Patients Leading to Early Diagnosis of Canadians in Heart Failure","Multidisciplinary Approach for High Risk Patients Leading to Early Diagnosis of Canadians","MAPLE-CHF","Inclusion Criteria:\n\n* Male or female \\> 40 years of age\n* Informed consent\n* At least two additional risk factors for Heart Failure (HF):\n\n  * Coronary artery disease (either a previous documented type 1 myocardial infarction or coronary artery bypass grafting or percutaneous coronary intervention or documented stenosis or an epicardial coronary artery (50% left main stem or \\>70% left anterior descending, circumflex or right coronary artery)).\n  * Diabetes type 1 or 2.\n  * Persistent or permanent atrial fibrillation.\n  * Previous ischemic or embolic stroke.\n  * Peripheral artery disease (previous surgical or percutaneous revascularization or documented stenosis \\>50% of major peripheral arterial vessel.\n  * Chronic kidney disease (defined as an estimated glomerular filtration rate (eGFR)\\\u003C60 milliliters per minute (mL\u002Fmin)\u002F1.73m2 or eGFR 60-90 mL\u002Fmin\u002F1.73m2 and urine albumin-creatinine ration (UACR) \\>300mg\u002Fg).\n  * Regular loop diuretic use for \\>30 days within 12 months prior to consent.\n  * Chronic obstructive pulmonary disease (COPD) evidenced by one of the following: Pulmonary Function Test (PFT) showing airway obstruction, diagnosis of respiratory physician, CT scan reporting presence of emphysema, or treatment with national guidance advocated COPD therapy.\n\nExclusion Criteria:\n\n* Inability to give informed consent (e.g. due to significant cognitive impairment).\n* Previous diagnosis of heart failure. This is any diagnosis of heart failure with any ejection fraction of any cause.\n* Renal replacement therapy.\n* Anyone who, in the investigator's opinion, is not suitable to participate in the trial for other reasons e.g., a diagnosis which may compromise survival over the study period.","ALL","40 Years",{"count":141,"type":142},1360,"ESTIMATED","INTERVENTIONAL",[145],"NA","The goal of this study is improve the screening of heart failure and identify patients early who are at risk of heart failure.\n\nThe main question\\[s\\] it aims to answer are:\n\n• will an electronic health records (EHR) case finding algorithm for heart failure, followed by N-Terminal pro-brain natriuretic peptide (NT-proBNP) screening and artificial intelligence (AI) echocardiogram compared to usual care identify patients at risk for heart failure earlier than standard of care?\n\nParticipants will be enrolled and randomized to either standard of care (SOC) or intervention arm:\n\nSOC arm: electronic health records will be reviewed over six months for assessments performed to identify heart failure.\n\nIntervention arm: blood sample for N-terminal prohormone of B-type natriuretic peptide (NT-proBNP) at local laboratory . For elevated NT-proBNP results (\\>125pg\u002Fml) an artificial intelligence (AI) echocardiogram and 12 lead electrocardiogram (ECG) will be performed at study site (within 28 days of NT-proBNP result). EHR will be reviewed at six months",[148],"Heart Failure",[150,151,152],"Heart failure screening","natriuretic peptides","artificial intelligence echocardiography","2024-03-05",{"date":155,"type":156},"2024-03-07","ACTUAL",{"date":158,"type":142},"2024-03-01",{"date":160,"type":142},"2029-01-01",{"name":5,"class":6},3]